| Title |
Economic burden of refractory chronic spontaneous urticaria on Kuwait's health system
|
|---|---|
| Published in |
ClinicoEconomics and Outcomes Research: CEOR, May 2016
|
| DOI | 10.2147/ceor.s98848 |
| Pubmed ID | |
| Authors |
Mona Al-Ahmad, Maryam S Alowayesh, Norman V Carroll |
| Abstract |
Chronic spontaneous urticaria (CSU) is a common problem worldwide. We evaluated the direct medical costs of treating patients with refractory CSU and the budget effect of omalizumab use in these patients in Kuwait. The prevalence of CSU was estimated using the Delphi method. Medical records of patients with refractory CSU in Kuwait were reviewed. Costs were calculated from a health system perspective. One-way sensitivity analyses were conducted on the price and utilization of each cost component. Before omalizumab use, the total direct costs of treating 1,293 patients with refractory CSU were estimated to be USD 3,650,733 per year. This estimation was principally generated by outpatient visits. After omalizumab use, the cost was sensitive to price variation and estimated to be USD 15,828,612 per year. All other direct costs were reduced. The economic burden of refractory CSU in Kuwait is high. Omalizumab use is costly, but its administration reduces all other direct costs. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 19 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 21% |
| Other | 2 | 11% |
| Professor | 1 | 5% |
| Student > Bachelor | 1 | 5% |
| Student > Ph. D. Student | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 9 | 47% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 21% |
| Economics, Econometrics and Finance | 2 | 11% |
| Business, Management and Accounting | 1 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Social Sciences | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 9 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 May 2016.
All research outputs
#20,011,936
of 25,457,297 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#395
of 525 outputs
Outputs of similar age
#217,511
of 312,056 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#18
of 26 outputs
Altmetric has tracked 25,457,297 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 525 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one is in the 15th percentile – i.e., 15% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,056 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one is in the 3rd percentile – i.e., 3% of its contemporaries scored the same or lower than it.